Edition:
United Kingdom

Nymox Pharmaceutical Corp (NYMX.OQ)

NYMX.OQ on NASDAQ Stock Exchange Capital Market

3.21USD
7:03pm GMT
Change (% chg)

$-0.03 (-0.93%)
Prev Close
$3.24
Open
$3.30
Day's High
$3.32
Day's Low
$3.21
Volume
11,121
Avg. Vol
29,822
52-wk High
$5.10
52-wk Low
$2.82

Latest Key Developments (Source: Significant Developments)

Nymox Pharmaceutical posts qtrly loss $0.09/shr - SEC filing‍​
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Nymox Pharmaceutical Corp :Nymox Pharmaceutical Corp qtrly loss per share $0.09 - SEC filing‍​.  Full Article

Nymox Pharmaceutical says ‍European member states accepted MAA​ for fexapotide triflutate
Thursday, 14 Sep 2017 

Sept 14 (Reuters) - Nymox Pharmaceutical Corp :Says ‍European member states for Nymox's MAA for fexapotide triflutate for treatment of benign prostatic hyperplasia accepted co's MAA​.  Full Article

Nymox Pharmaceutical reports results of prostate cancer study
Wednesday, 22 Jun 2016 

Nymox Pharmaceutical Corp : Nymox reports long-term prostate cancer results in 7 year prospective study of 995 u.s. Middle-Aged and elderly men without cancer . Men who received fexapotide showed a major reduction in incidence of prostate cancer, compared to placebo . Men who received fexapotide showed major reduction in incidence of prostate cancer versus placebo and versus known and expected normal incidence of disease .New data analysis has now shown statistically significant and very low incidence of 1.3% for prostate cancer in comparable fexapotide treated bph population.  Full Article

Nymox Pharmaceutical Corp announces prostate cancer clinical trial results from completed 18 month endpoint study
Tuesday, 9 Feb 2016 

Nymox Pharmaceutical Corp:Announces prostate cancer clinical trial results from completed 18 month endpoint study.Says the study successfully met its pre-determined endpoints.Says cancer progression clinical outcomes were significantly improved in the fexapotide treated patient groups.  Full Article

Nymox Pharmaceutical Corp announces additional $2.1 mln equity financing
Thursday, 4 Feb 2016 

Nymox Pharmaceutical Corp:Announces additional $2.1 million equity financing.Says has now closed private placements totalling $3.4 million since November 5.Says the investment was at $2.00 per share with no warrants.  Full Article

BRIEF-Nymox Pharmaceutical posts qtrly loss $0.09/shr - SEC filing‍​

* Nymox Pharmaceutical Corp qtrly loss per share $0.09 - SEC filing‍​ Source text: (http://bit.ly/2j7iBgX) Further company coverage: